Teva Spikes 12% After Q2 Earnings Beat and Guidance Raise

5
Comment
Favorite

Teva Spikes 12% After Q2 Earnings Beat and Guidance Raise

seekingalpha2023-08-02

Teva Pharmaceutical added more than 12% in morning trading on Wednesday after its Q2 2023 results, as the generic drugmaker lifted the mid-point of its full-year revenue outlook and posted its first ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2356018292?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-08-02 22:15","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2356018292","market":"us","top_or_hot":-1,"title":"Teva Spikes 12% After Q2 Earnings Beat and Guidance Raise","media":"seekingalpha","content":"<div>\n<p>Teva Pharmaceutical added more than 12% in morning trading on Wednesday after its Q2 2023 results, as the generic drugmaker lifted the mid-point of its full-year revenue outlook and posted its first ...</p>\n\n<a href=\"https://seekingalpha.com/news/3995020-teva-pharmaceutical-beats-q2-top-and-bottom-line-estimates-raises-fy23-revenue-outlook\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Teva Spikes 12% After Q2 Earnings Beat and Guidance Raise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTeva Spikes 12% After Q2 Earnings Beat and Guidance Raise\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-08-02 22:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3995020-teva-pharmaceutical-beats-q2-top-and-bottom-line-estimates-raises-fy23-revenue-outlook><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Teva Pharmaceutical added more than 12% in morning trading on Wednesday after its Q2 2023 results, as the generic drugmaker lifted the mid-point of its full-year revenue outlook and posted its first ...</p>\n\n<a href=\"https://seekingalpha.com/news/3995020-teva-pharmaceutical-beats-q2-top-and-bottom-line-estimates-raises-fy23-revenue-outlook\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"https://seekingalpha.com/news/3995020-teva-pharmaceutical-beats-q2-top-and-bottom-line-estimates-raises-fy23-revenue-outlook","article_id":"2356018292","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2356018292","pubTimestamp":1690985723,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Teva Pharmaceutical press release  : Q2  Non-GAAP EPS of $0.56  beats by $0.03.Cash flow generated from operating activities of $324 million.2023 revenues outlook revised to $15.0-$15.4 billion from $14.8-$15.4 billion vs. consensus of $15.02B; all other key components reaffirmed: Non-GAAP operating Income of $4.0 – $4.4 billion; Adjusted EBITDA of $4.5 - $4.9 billion; Non-GAAP diluted EPS of $2.25 - $2.55 vs. consensus of $2.29; Free cash flow of $1.7 - $2.1 billion.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"Teva在第二季度收益超过预期和指导上调后上涨12%","themeId":"c0d77e622a6742cf8335299f8317b4b4","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical added more than 12% in morning trading on Wednesday after its Q2 2023 results, as the generic drugmaker lifted the mid-point of its full-year revenue outlook and posted its first quarterly earnings beat in three quarters.Israel-based TEVA reported $3.9B in revenue for the quarter, indicating ~2% YoY growth, while in local currency terms, its revenue expanded ~4% YoY, thanks to its generic products in international markets and drugs such as Anda and Austedo in North America.\"With this solid performance, we are slightly increasing the midpoint of our revenue guidance for the year and reaffirming all other guidance items,\" CEO Richard Francis said.Teva (TEVA) increased the lower end of the previously announced revenue guidance while reaffirming all other elements of its outlook. Its revised revenue guidance of $15.0B - $15.4B is in line with the consensus of $15.02B.During the quarter, TEVA recorded $2.0B in revenue from North America, with ~5% YoY growth. Sales of Anda and Austedo from the region brought $392M and $308M to the topline with ~27% YoY and ~51% YoY growth, respectively, while contributions from generic products slipped ~6% YoY to $969M.The European markets generated $1.2B in revenue with a ~1% YoY decline driven by a $1M hedging impact even as sales of the company’s generic products grew ~4% YoY to $909M.Meanwhile, Teva’s (TEVA) non-GAAP gross profit margin slipped to 52.2% in Q2 2023 from 54.4% in the prior year due to inflationary and other macroeconomic pressures as well as unfavorable changes to product mix.All in all, the company’s adj. net income fell ~17% YoY to $629M while its cash flow from operating activities as well as free cash flow more than doubled to $324M and $632M, respectively.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}